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Plasminogen activator inhibitor-1 deficiency retards diabetic
nephropathy.
Background. Plasminogen activator inhibitor-1 (PAI-1) is
increased in kidneys of humans and animals with diabetic
nephropathy and is associated with extracellular matrix (ECM)
accumulation. PAI-1 may promote ECM buildup by prevent-
ing plasmin and matrix metalloproteinase (MMP) activation.
However, the importance and mechanism of PAI-1 action in
the pathogenesis of diabetic nephropathy is unknown.
Methods. We investigated the effect of streptozotocin (STZ)-
induced diabetes in wild-type (PAI-1+/+) mice and mice null
for PAI-1 (PAI-1−/−). After 1 month of diabetes, animals were
placed in metabolic cages for 24-hour urine collection. Total
RNA was isolated from kidney cortex for reverse transcription-
polymerase chain reaction (RT-PCR) and Northern blot anal-
ysis, and Western blots were quantitated from cortical protein.
Primary mesangial cells were grown from Sprague-Dawley rats
and used in signal transduction studies.
Results. Urinary albumin excretion (UAE) in diabetic PAI-
1+/+ mice increased >threefold, but remained unchanged in
PAI-1−/− mice. Transforming growth factor-b (TGF-b) and fi-
bronectin message and protein levels were lower in diabetic
PAI-1−/− vs. PAI-1+/+ mice, suggesting that PAI-1 deficiency
impaired TGF-b expression despite diabetes. Indeed, recombi-
nant PAI-1 directly stimulated TGF-b message and protein via
mitogen-activated protein kinase (MAPK) signal transduction
in cultured mesangial cells. Urokinase plasminogen activator
(uPA) inhibited this PAI-1 action in a dose-dependent manner.
The inhibitory effect of antibody to uPA receptor (uPAR) on
PAI-1–induced TGF-b function suggested that uPAR mediated
the cellular effect of PAI-1.
Conclusion. PAI-1 can regulate TGF-b expression by binding
to uPAR and activating the extracellular-regulated signal kinase
(ERK)/MAPK pathway. Therefore, PAI-1 contributes to dia-
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betic nephropathy by regulating TGF-b and renal ECM produc-
tion and may be a therapeutic target in diabetic nephropathy.
Plasminogen activator inhibitor-1 (PAI-1) prevents
conversion of tissue plasminogen activator and urokinase
plasminogen activator (uPA) to plasminogen [1]. Plas-
min, the active form of plasminogen, is a broad-spectrum
protease that degrades fibrin clots and extracellular ma-
trix (ECM) proteins. As a result, PAI-1 is an important
regulator of both fibrinolysis and tissue remodeling. PAI-
1 levels are normally tightly regulated to maintain home-
ostasis of both processes. A deficiency in PAI-1 results
in hemorrhage [2–4], while overexpression is prothrom-
botic contributing to coronary events and deep venous
thrombosis [1]. PAI-1 is thought to promote tissue fi-
brosis by inhibiting plasmin and metalloproteinase ECM
degradation [5]. It has been implicated in experimental
glomerulonephritis [6], chronic renal transplant rejection
[7], and pulmonary fibrosis [8]. Transgenic mice over-
expressing PAI-1 develop significantly greater pulmonary
fibrosis when administered bleomycin, while similarly
treated PAI-1–deficient mice have substantially less fibro-
sis compared to wild-type mice [9]. PAI-1 deficiency also
protects against renal interstitial fibrosis induced by uni-
lateral ureteral obstruction (UUO) [10]. More recently,
a mutant human PAI-1 that could bind to vitronectin but
not inhibit plasminogen activator–decreased ECM accu-
mulation in experimental glomerulonephritis [11].
In diabetic nephropathy, accumulation of ECM pro-
teins in the mesangium leads to glomerulosclerosis,
the hallmark of diabetic nephropathy [12]. In nor-
mal human kidney, PAI-1 levels are undetectable, but
in diabetes, PAI-1 expression is up-regulated in renal
glomeruli and arteries [13]. The increased glomerular
PAI-1 accompanies microangiopathic injury and accu-
mulation of ECM in patients with diabetes and may
1297
1298 Nicholas et al: PAI-1 deficiency and diabetic nephropathy
indicate a worse prognosis [14]. The increase in tis-
sue PAI-1 likely occurs in response to factors inherent
to the diabetic environment such as increased trans-
forming growth factor-b (TGF-b), hyperglycemia, very
low-density lipoprotein (VLDL) triglycerides, and an-
giotensin II (Ang II), all of which activate the PAI-1
promoter [15].
To more precisely determine the role of PAI-1 in dia-
betic nephropathy, we induced diabetes in genetically de-
ficient PAI-1 (PAI-1−/−) mice with streptozotocin (STZ)
(Sigma Chemical Co., St. Louis, MO, USA). Lack of PAI-
1 prevented albuminuria and accumulation of fibronectin
mRNA and protein, a major ECM component. However,
renal matrix metalloproteinase (MMP)-9 and MMP-2 ac-
tivities were not increased in diabetic PAI-1−/− mice. On
the other hand, both TGF-b mRNA and protein levels
were significantly reduced in diabetic PAI-1−/− mice com-
pared to diabetic wild-type (PAI-1+/+) mice. Consistent
with this observation, we found that PAI-1 directly reg-
ulates TGF-b expression in mesangial cells by binding
to uPA receptor (uPAR) and activating the extracellular-
regulated signal kinase (ERK)/mitogen-activated protein
kinase (MAPK) pathway. Thus, the lack of PAI-1 likely
is associated with a decrease in ECM production con-
tributing to decreased ECM accumulation in diabetes.
Targeting PAI-1 may be a useful therapeutic strategy to
prevent glomerular fibrosis and proteinuria in diabetic
nephropathy.
METHODS
Mouse breeding and measurements
PAI-1–deficient (PAI-1−/−) mice on a C57B/L6 back-
ground (breeding pairs) and wild-type C57B/L6 (PAI-
1+/+) mice (Jackson Laboratory, Bar Harbor, ME, USA)
were housed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals and placed on a
protocol approved by the Animal Research Committee
of the University of California, Los Angeles. Mice were
ad libitum in isolation-topped cages under a 12-hour light-
dark regime. Ten-week-old mice were divided into non-
diabetic PAI-1+/+ (N = 14), diabetic PAI-1+/+ (N = 15),
nondiabetic PAI-1−/− (N = 16), and diabetic PAI-1−/−
(N = 13) mice. Diabetes was induced with a single in-
traperitoneal injection of STZ (Sigma Chemical Co.),
120 to 180 mg/kg body weight to achieve plasma glu-
cose ≥300 mg/dL after 5 to 7 days. Plasma glucose, from
retro-orbital blood, was determined by glucose oxidase
reaction (Beckman Glucose Analyzer 2; Beckman In-
struments, Fullerton, CA, USA). Weekly blood pressures
were obtained from trained, prewarmed mice by com-
puterized, noninvasive tail-cuff system (BP 2000 Blood
Pressure Analysis System) (Visitech Systems, Apex, NC,
USA) [16].
Animals were placed in metabolic cages for 24-hour
urine collection. Albumin concentrations were measured
using the Albuwell M Assay Kit (Exocel, Philadelphia,
PA, USA). Albumin standards and samples were placed
in 96-well plates, and washed with rabbit antimurine al-
bumin antibody and antirabbit horseradish peroxidase
(HRP) conjugate for color detection at 450 nm ab-
sorbance used to calculate albumin concentration.
Quantitative reverse transcription (RT) real-time
polymerase chain reaction (PCR)
Total RNA (45 lg) isolated from mouse kidney cor-
tex or primary mesangial cells by Trizol method (In-
vitrogen Life Technologies, Carlsbad, CA, USA) was
DNase-treated and (200 ng) reverse transcribed us-
ing Applied Biosystems Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA, USA) with a
parallel negative control. Triplicate PCR amplifications
of cDNA (5 ng) were performed with the follow-
ing primers (200 nmol/L) and probes (100 nmol/L)
(Perkin-Elmer/Applied Biosystems PE/ABD Primer Ex-
press Software): PAI-1 forward primer 5′-TGC ATC
GCC TGC CAT TG-3′; PAI-1 reverse primer 5′-
GGA CCT TGA GAT AGG ACA GTG CTT-3′;
PAI-1 probe 5′-6FAM TGG AGG GTG CCA TGG
GCC A TAMRA-3′; fibronectin forward primer 5′-
TGT AGG AGA ACA GTG GCA GAA AGA-3′;
fibronectin reverse primer 5′-CCG CTG GCC TCC
GAA-3′; fibronectin probe 5′-6FAM TCG GAG CCA
TTT GTT CCT GCA CGT TAMRA-3′; TGF-b for-
ward primer 5′-CCA TCC ATG ACA TGA ACC GA-3′;
TGF-b reverse primer 5′-CAG GTG TTG AGC CCT
TTC CA-3′; and TGF-b probe 5′-/56-FAM/CCA-TCC-
TTT-CCC-ATA-TCC-TGT-CC/36-TAMTPH/−3′. PCR
amplification [including glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH)] was performed (Perkin-Elmer/
Applied Biosystems 7700 Sequence Detector) with nega-
tive RT controls to detect contaminating genomic DNA.
The data were analyzed using Perkin-Elmer Applied
Biosystems Sequence Detection System software.
Northern blot analysis
Northern blot analysis was performed on total RNA
(20 lg) from mouse kidney cortex which was care-
fully dissected from the renal capsule and medulla
[17]. RNA separated by electrophoresis was transferred
to nylon membranes (Hybond N+) (Amersham Bio-
sciences, Buckinghamshire, UK) which were probed with
32P-labeled TGF-b or fibronectin cDNA (generously
provided by Matthew Breyer, Vanderbilt University).
Signals were detected by autoradiography (Amersham
Biosciences) scanned and quantitated using NIH Image
1.60 and Image J version 1.28U scan software.
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MMP assays
Protein isolated from mouse renal cortex was homog-
enized, quantitated, and used in MMP assays (Amer-
sham Biosciences). Duplicate standard (0 to 16 ng/mL)
and experimental samples were placed in 96-well plates
for determination of endogenous and active MMP-9 and
MMP-2. The plates were read at 405 nm at time zero and
after 4 to 10 hours. Active MMP-9 and MMP-2 activity
was determined from standard curves and analyzed by
standard Student t test.
Mesangial cell culture
Rat glomeruli were isolated from normal Sprague-
Dawley rats (200 to 650 g) (Charles River, Boston, MA,
USA) by the sieving technique as previously published
[18]. Glomerular cores collected in phosphate-buffered
saline (PBS) were resuspended in Dulbecco’s modied
Eagle’s medium (DMEM) containing D-valine (inhibits
fibroblast growth), and 1 lmol/L recombinant human in-
sulin (Sigma Chemical Co.). Mesangial cells were grown
and characterized by phenotype and immunostaining
to verify >95% mesangial cells. The stellate-appearing
mesangial cells stained positive for fibronectin and a-
smooth muscle actin (a-SMA) (Sigma Chemical Co.), and
negative for cytokeratin. We used nonconfluent, serum-
starved 0.5% fetal bovine serum (FBS) × 24 hours cells
between passages 9 and 10 following a 30-minute pre-
treatment.
Cells were acid washed [19, 20] to remove plasminogen
and endogenous uPA prior to addition of exogenous uPA
or recombinant PAI-1 as follows. Cells were incubated in
glycine buffer at pH 4.0 × 3 minutes at 4◦C followed by
neutralization with Tris buffer at pH 7.4 × 10 minutes.
This was followed by addition of exogenous uPA or PAI-
1 as described.
Mouse mesangial cells were also obtained from PAI-
1−/− mice by the sieving technique described above and
treated with varying concentrations of glucose, compared
to similarly treated mesangial 13 PAI-1+/+ cells (Ameri-
can Type Culture Collection, Manassas, VA, USA).
Western blot analysis
Western blot analysis was done by standard procedures
using 40 to 100 lg protein from PAI-1−/− and PAI-1+/+
renal cortex. Membranes were probed with TGF-b anti-
mouse primary antibody (BD Biosciences/Pharmingen,
San Diego, CA, USA) (1:100) or fibronectin antimouse
monoclonal and rabbit secondary antibody (Chemicon
International, Temecula, CA, USA) (1:1000). The sig-
nals were scanned and quantitated using the Image J
version 1.28 U and NIH Image 1.60 scan software. Pro-
tein was also obtained from primary rat mesangial cells
treated with recombinant PAI-1 (0 to 30 nmol/L) for 0 to
24 hours or pretreated with the MAPK inhibitor PD98059
to detect TGF-b protein. Protein for phosphorylated
and total p44/p42 ERK/MAPK protein expression was
detected using phosphorylated MAPK p44/ERK1 and
MAPK p42/ERK2 primary antibodies (New England
Biolabs, Beverly, MA, USA) (1:1000) and corresponding
secondary antibody. Following enhanced chemilumines-
cence (ECL) detection of proteins, the membranes were
stripped and rehybridized with total MAPK p44/ERK1
and MAPK p42/ERK2 antibodies. At least three cell
preparations were used.
Statistical analysis
Data are expressed as the mean ± SEM. Statistical
analysis was performed using Sigma Plot statistical 5.0
software (SPSS, Chicago, IL, USA). Differences in mean
values between groups were analyzed by Student t test.
RESULTS
Characteristics of wild-type and PAI-1–deficient mice
STZ administration increased plasma glucose
>500 mg/dL in PAI-1–deficient (PAI-1−/−) and wild-
type (PAI-1+/+) mice 5 to 7 days following STZ injection
(Table 1). There was no statistical difference in baseline
or final plasma glucose measurements between PAI-1−/−
and PAI-1+/+. After 4 weeks, nondiabetic mice tended to
increase their body weight, while diabetic PAI-1+/+ and
PAI-1−/− mice lost 15% and 20% body weight, respec-
tively (P < 0.05). However, both PAI-1+/+ and PAI-1−/−
mice had increased kidney weight-to-tibia length ratios
(∼12%) (P < 0.05) compared to nondiabetic animals.
Thus, both PAI-1+/+ and PAI-1−/− mice demonstrated
renal hypertrophy with diabetes. In addition, all diabetic
animals increased 24-hour urine volume tenfold (P <
0.05), consistent with hyperglycemia. There was no
difference in tail-cuff blood pressures in nondiabetic or
diabetic mice.
Diabetes increased total urinary albumin excretion
(UAE) in PAI-1+/+ but not PAI-1−/− mice
PAI-1 was not expressed in kidneys of PAI-1−/− mice
with or without diabetes (Fig. 1A). However, PAI-1 ex-
pression increased 1.5-fold (P < 0.05) in diabetic PAI-
1+/+ kidneys compared to nondiabetic PAI-1+/+ mice.
Baseline UAE between nondiabetic PAI-1−/− (30.5 ±
4.2 lg) and PAI-1+/+ mice (20.3 ± 4.3 lg) was not sig-
nificantly different. Diabetic PAI-1+/+ mice increased
UAE >threefold compared to nondiabetic PAI-1+/+
mice (62.3 ± 13.9 vs. 20.3 ± 4.3 lg) (P < 0.05) (Fig. 1B).
In contrast, there was essentially no change in UAE in di-
abetic PAI-1−/− mice following 4 weeks of diabetes (1.1-
fold) (30.5 ± 4.2 vs. 35.0 ± 3.0 lg). Thus, lack of PAI-1
protects against albuminuria induced by diabetes.
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Table 1. Physiologic characteristics of mice
PAI-1+/+ PAI-1−/−
Nondiabetic Diabetic Nondiabetic Diabetic
(N = 14) (N = 15) (N = 16) (N = 13)
Body Weight, initial g 26.2 ± 0.5 25.3 ± 0.4 25.3 ± 0.5 24.1 ± 0.7
Body Weight, final g 27.2 ± 0.5 21.7 ± 0.9a 26.7 ± 0.6 19.5 ± 1.1a
Plasma glucose, initial mg/dL 166.7 ± 3.5 514.5 ± 50.8a 192.8 ± 11.1 652.3 ± 25.1a
Plasma glucose, final mg/dL 246.9 ± 21 589.2 ± 37.3a 214.1 ± 14.9 686.3 ± 17.3a
Urine volume mL 0.98 ± 0.15 10.0 ± 2.8a 1.08 ± 0.16 9.7 ± 1.1a
Blood Pressure mm/Hg 102.9 ± 2.6 96.9 ± 3.8 99.9 ± 2.4 104.4 ± 1.1
Kidney weight/tibia length × 10−3 9.5 ± 0.2 10.8 ± 0.4a 9.6 ± 0.3 10.7 ± 0.4a
PAI-1 is plasminogin activator inhibitor-1.
PAI-1+/+ are wild-type mice, and PAI-1−/− are PAI-1 knock-out mice.
aP < 0.05 vs. non diabetic mice. Values are mean ± SEM.
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Fig. 1. Plasminogen activator inhibitor-1 (PAI-1) expression and total
urinary albumin excretion (UAE). (A) Kidney cortex total RNA from
PAI-1–deficient (PAI-1−/−) and wild-type (PAI-1+/+) mice was used
to quantitate PAI-1 and glyceraldehyde-3-phosphate dehyrogenase
(GAPDH) expression by quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR). The fold change in PAI-1 ex-
pression is compared to GAPDH (N = 8). (B) After 4 weeks, mice
were placed in metabolic cages for 24-hour urine collection. Total UAE
(lg) was determined by enzyme-linked immunosorbent assay (ELISA):
nondiabetic (Non-DM), PAI-1+/+ (N = 14), diabetic (DM) PAI-1+/+
(N = 15), non-DM PAI-1−/− (N = 16), and DM PAI-1−/− (N = 13)
mice. Values are expressed as mean ± SEM ∗P < 0.05.
MMP activity is reduced in diabetic PAI-1−/− mice
MMP-2 and MMP-9 are the major glomerular MMPs.
Renal levels and activity of MMP-9 are decreased in ex-
perimental and human diabetes [21]. Nondiabetic PAI-
1−/− mice trended toward higher renal MMP-9 activity
compared to nondiabetic PAI-1+/+ mice, which was not
statistically significant (Fig. 2A). With diabetes, MMP-9
activity decreased to similar levels in both PAI-1+/+ and
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Fig. 2. Matrix metalloproteinase (MMP) activity. After 4 weeks, pro-
tein obtained from mouse kidney cortex was used for active MMP-9
(A) and MMP-2 (B) concentration. Nondiabetic (Non-DM), plasmino-
gen activator inhibitor-1 (PAI-1)+/+ (N = 14), diabetic (DM) PAI-1+/+
(N = 15), non-DM PAI-1−/− (N = 16), and DM PAI-1−/− (N = 13)
mice. Values are expressed as mean ± SEM ∗P < 0.05.
PAI-1−/− mice, which was not different between strains.
Renal MMP-2 activity was not different in the absence
of diabetes between strains (Fig. 2B). However, MMP-2
activity was significantly lower in diabetic PAI-1−/− com-
pared to nondiabetic PAI-1−/− (P < 0.05) or PAI-1+/+
mice. These patterns are consistent with observations of
different tissue expression patterns and transcriptional
regulation of MMP-9 and MMP-2 [22].
Fibronectin and TGF-b expression is reduced in diabetic
PAI-1−/− mice
Fibronectin is the earliest and most abundant ECM
protein to increase in kidney and other tissues in diabetes
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Fig. 3. Fibronectin and transforming growth
factor-b (TGF-b) mRNA and protein expres-
sion. (A) Quantitative reverse transcription-
polymerase chain reaction (RT-PCR) of ratio
of fibronectin to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA expres-
sion in mouse kidney cortex. (B) Representa-
tive Western blot analysis of fibronectin and
b-actin protein. (C) Graphic representation of
Western blots of fibronectin and b-actin. (D)
Quantitative RT-PCR of ratio of TGF-b to
GAPDH mRNA expression in mouse kidney
cortex. (E) Representative Northern blot of
TGF-b and GAPDH mRNA expression. (F)
Graphic representation of fold change from
Northern blots of TGF-b and GAPDH. (G)
Representative Western blot analysis of TGF-
b and b-actin protein. (H) Graphic repre-
sentation of Western blots from TGF-b and
b-actin. Tissue from at least eight animals
per group was used for each experiment. ∗P
< 0.05 compared with control. (I) Primary
mouse mesangial cells from plasminogen ac-
tivator inhibitor-1 (PAI-1)−/− mice and PAI-
1+/+ mouse cells (mesangial cell 13 stable cell
line) were incubated with glucose for 24 hours.
TGF-b and b-actin protein expression was de-
termined as shown in the representative West-
ern blot and quantitated. (J) At lease four sep-
arate cell preparations were used. ∗P < 0.05
compared with control.
[23]. Levels of standardized fibronectin mRNA and pro-
tein were 2.6-fold higher (3.7 ± 0.5 vs. 9.5 ± 1.3) and
3.5-fold higher, respectively, in diabetic PAI-1+/+ com-
pared to nondiabetic PAI-1+/+ mice, while basal levels
were not different between PAI-1+/+ and PAI-1−/− mice
(P < 0.05) (Fig. 3A to C). In contrast, diabetes did not
significantly alter fibronectin mRNA expression in PAI-
1−/− mice. In fact, fibronectin protein was 50% less in
diabetic PAI-1−/− compared to diabetic PAI-1+/+ mice
(P < 0.05). These results suggest that diabetic PAI-1−/−
mice do not accumulate fibronectin.
TGF-b expression and activity increase in experimen-
tal and human diabetes. Therefore, we expected equally
increased renal TGF-b levels in PAI-1+/+ and PAI-1−/−
mice with diabetes. However, we did not observe these
predicted changes. Renal TGF-b mRNA levels increased
∼1.5-fold (P < 0.05) in diabetic PAI-1+/+ mice, but not
in PAI-1−/− mice when assessed by either RT-PCR or
Northern analysis (Fig. 3D to F). TGF-b protein was also
significantly less in diabetic PAI-1−/− (P < 0.05) com-
pared to nondiabetic PAI-1−/− mice (Fig. 3G and H).
Thus, diabetic PAI-1−/− had less renal TGF-b mRNA
and protein compared to PAI-1+/+ mice, suggesting that
PAI-1 may potentially transcriptionally regulate TGF-b .
Additional studies were performed in which pri-
mary mesangial cells obtained from PAI-1−/− mice were
treated with glucose (0, 4, and 30 mmol/L) for 24 hours in
parallel with PAI-1+/+ mouse mesangial cells (mesangial
cell 13 stable cell line). We observed a dose-dependent
increase in TGF-b protein expression (Fig. 3I and J) with
increasing glucose concentrations in PAI-1+/+ cells and
no regulation of TGF-b protein in PAI-1−/− cells.
Recombinant PAI-1 stimulated TGF-b production by
MAPK signal transduction
To determine whether PAI-1 might have a direct effect
on TGF-b , we incubated primary mesangial cells with
recombinant PAI-1 (0 to 30 nmol/L) and examined TGF-
b protein expression between 0 and 24 hours. PAI-1 in-
creased TGF-b protein in a dose-dependent manner up
to 40 minutes (Fig. 4A and B), to approximately three-
fold at 30 nmol/L PAI-1. The increase continued up to
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2 hours then tapered over 24 hours (data not shown).
Preincubation with the MAPK inhibitor, PD98059, com-
pletely abolished the PAI-1–induced TGF-b mRNA and
protein increases (Fig. 4C to E). As anticipated, PD98059
also caused a significant reduction in the ratio of phospho-
rylated to total MAPK p42/ERK1 and MAPK p44/ERK2
protein expression (Fig. 4F and G).
Recombinant PAI-1 stimulated TGF-b
via a uPAR mechanism
In several cell types, PAI-1 interacts with uPA bound to
its cell surface receptor uPAR, which also interacts with
integrins [1, 24]. When the uPA•PAI-1•uPAR complex is
formed, the integrin is inactivated so that the complex is
internalized and promotes downstream intracellular sig-
naling of ERK/MAPK [25]. PAI-1 can also independently
recruit uPAR without uPA to potentially activate intra-
cellular signaling pathways [26]. When added to cultured
mesangial cells which were acid-washed (to remove plas-
minogen and endogenous uPA), recombinant PAI-1 or
uPA independently stimulated TGF-b expression (P <
0.05) (Fig. 5A and B). However, blockade of uPA bind-
ing with CD87, an anti-uPAR antibody which blocks the
amino terminal domain of uPA that binds uPAR and pre-
vents uPA/PAI-1 internalization [27, 28], abolished PAI-
1–induced TGF-b regulation. Excess uPA (50 nmol/L)
significantly reduced PAI-1–induced TGF-b expression
in a dose-dependent (5 to 50 nmol/L) manner (Fig. 5C
and D). These data indicate that stimulation of TGF-b
by PAI-1 is mediated by uPAR.
DISCUSSION
The availability of mice genetically lacking PAI-1 al-
lowed us to elucidate the role of this profibrotic factor in
diabetic nephropathy and to define a potential new mech-
anism that mediates glomerular fibrosis. STZ-induced di-
abetic PAI-1−/− mice did not develop albuminuria, while
PAI-1+/+ mice demonstrated a >threefold increase in
UAE. The PAI-1−/− mice also had no increase in renal
fibronectin mRNA or protein levels compared to PAI-
1+/+ mice. This apparent decreased ECM accumulation
in PAI-1−/− mice could not be explained by increased
MMP activity, since MMP-9 and MMP-2 activities were
not increased in diabetic PAI-1−/− compared to PAI-1+/+
mice. Therefore, decreased production, possibly associ-
ated with degradation of ECM, likely occurred in PAI-
1−/− mice. Indeed, PAI-1−/− mice had decreased renal
TGF-b mRNA expression and protein levels compared
to diabetic PAI-1+/+ mice, which likely contributed to the
decreased renal fibronectin message and protein that ac-
companied attenuated albuminuria. These observations
were supported by in vitro studies in which recombinant
PAI-1 caused a dose-dependent increase in TGF-b pro-
tein levels in cultured mesangial cells. Taken together,
these data suggest that PAI-1 plays a critical role in dia-
betic nephropathy by regulating TGF-b expression and
protein, which is an important determinant of both ECM
production and degradation.
STZ-induced diabetes in rats and mice results in early
renal changes similar to that seen in humans with dia-
betes. These changes include increased albumin excretion
and renal TGF-b expression, leading to enhanced pro-
duction of fibronectin and other ECM proteins [29, 30].
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Fig. 4. Recombinant plasminogen activator inhibitor-1 (PAI-1) stimu-
lated transforming growth factor-b (TGF-b) expression by extracellular-
regulated signal kinase (ERK)/mitogen-activated protein kinase
(MAPK) signal transduction. Primary rat mesangial cells from Sprague-
Dawley rats were serum-starved and treated with varying concentra-
tions of recombinant rat PAI-1. (A) Representative Western blot of
TGF-b and b-actin expression. (B) Graphic representation of fold
change in signals from Western blot. (C) Primary rat mesangial cells
were untreated, treated with recombinant rat PAI-1 or pretreated
with the MAPK inhibitor, PD98059 Quantitative reverse transcription-
polymerase chain reaction (RT-PCR). (D) Representative Western blot
of TGF-b protein. (E) Graphic representation of Western blot analysis
of TGF-b to b-actin protein. (F) Representative Western blot of phos-
phorylated and total p42/ERK and p44/ERK, corresponding to protein
bands 44 and 42 kD bands, respectively. (G) Graphic representation of
ratio of phosphorylated to total p42/ERK, p44/ERK. Values are mean ±
SEM. ∗P < 0.05 compared to control. Each experiment was performed
at least three times.
In man, the resulting increased mesangial volume corre-
sponds to albuminuria and loss of glomerular filtering ca-
pacity, ultimately progressing to end-stage renal disease
(ESRD) [31]. Inhibition of TGF-b with either blocking
antibodies or decorin, a natural TGF-b inhibitor, arrests
the process in animals [32]. These observations support
a pathophysiologic role for TGF-b in diabetic nephropa-
thy, although other factors may be involved. Thus, under-
standing the mechanisms that regulate TGF-b is key in
prevention and treatment of diabetic nephropathy. Ad-
ministration of angiotensin converting enzyme (ACE) in-
hibitors or Ang II type 1 (AT1) receptor blockers (ARBs)
attenuate the progression of diabetic nephropathy in hu-
mans and are associated with both decreased urinary
TGF-b [33, 34] and tissue PAI-1 [35, 36]. Ang II is a
potent regulator of PAI-1 in mesangial cells and PAI-1
may be more sensitive to Ang II stimulation than TGF-b
(Nicholas, Hsueh unpublished observations). The present
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Fig. 4. (continued)
investigation identifies PAI-1 as a potentially important
regulator of TGF-b in the glomerulus. Hyperglycemia is
known to stimulate TGF-b production in mesangial cells.
Further, PAI-1 may mediate, at least in part, the glycemic
effect on TGF-b , since mesangial cells obtained from
PAI-1−/− mice showed no regulation of TGF-b expres-
sion in response to hyperglycemia compared to PAI-1+/+
mouse cells. Indeed, hyperglycemic response elements
have been demonstrated on the PAI-1 promotor [37].
Our studies suggest that the mechanism by which mice
null for PAI-1 are protected against diabetic nephropathy
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Fig. 5. Mechanism of plasminogen activator inhibitor-1 (PAI-1) induc-
tion of transforming growth factor-b (TGF-b) expression. Primary rat
mesangial cells were untreated (lane 1), treated with recombinant PAI-1
(lane 2), urokinase plasminogin activator (uPA) (lane 3), or pretreated
with anti-uPA receptor (uPAR) (lane 4) or uPA followed by PAI-1 (lane
5). (A) Representative Western blot of TGF-b expression. Anti-uPAR,
inhibited PAI-1–stimulated TGF-b expression (lane 4). Excess uPA pre-
vented PAI-1–stimulated TGF-b expression. (B) Graphic representa-
tion of TGF-b/b-actin protein ratio of at least four separate experi-
ments. ∗P < 0.05 compared to untreated (lane 1). #P < 0.05 compared
to PAI-1–stimulated TGF-b expression (lane 2). (C) Rat mesangial cells
were incubated with recombinant PAI-1 and uPA Representative West-
ern blot. (D) Graphic representation of three separate experiments. ∗P
< 0.05 compared to PAI-1 alone. Each experiment was performed at
least three times.
involves regulation of TGF-b , as a more prominent mech-
anism than increased plasmin and MMP activation poten-
tially associated with lack of PAI-1. MMP-9 and MMP-
2 are the major glomerular MMPs [38, 39]. MMP-9 is
activated by plasmin and transcriptionally regulated by
both TGF-b and hyperglycemia. MMP-2 is not regu-
lated by plasmin but may be activated by membrane-
type MMPs, particularly membrane type 1-MMP [21, 40–
43]. Although the physiologic regulation of membrane
type 1-MMP is not fully characterized, hyperglycemia
may down-regulate its activity [44]. Our results were
surprising in that, neither MMP-9 nor MMP-2 activities
were increased in diabetic PAI-1−/− vs. PAI-1+/+ mice; in
fact MMP-2 was decreased. Decreased TGF-b expression
could account for decreased MMP-9 and hyperglycemia
for the decreased MMP-2 [39]. Despite the cause, lack
of increased renal MMP activity argues against acceler-
ated degradation of ECM as the major mechanism for
attenuation of ECM accumulation in PAI-1−/− mice.
Similar to results of our study, PAI-1−/− mice subjected
to UUO developed less renal interstitial fibrosis com-
pared to PAI-1+/+ mice [10]. Kidneys of PAI-1−/− mice
had decreased TGF-b and collagen expression without
increases in uPA or plasmin activity compared to PAI-
1+/+ mice. Since plasmin activates TGF-b membrane-
release [45], the lack of increased TGF-b is consistent
with a lack of increased plasmin that might be anticipated
in PAI-1+/+ mice [10]. Increased interstitial macrophages
and myofibroblasts in the fibrotic kidneys of PAI-1+/+,
but not PAI-1−/− mice, was thought to account for de-
creased TGF-b in PAI-1−/− mice. Decreased fibrosis in
this model was attributed to decreased PAI-1-induced cell
chemotaxis. In the immune anti-Thy-1 model of glomeru-
lonephritis, which demonstrates glomerular expansion
and macrophage/monocyte infiltration but no interstitial
fibrosis, the administration of a mutant PAI-1 resulted
in increased plasmin activity with subsequent reduced
glomerular matrix accumulation within 6 days com-
pared to untreated animals. However, TGF-b mRNA
and protein were reduced with subsequent reduction
in fibronectin and collagen 1 mRNA levels. Decreased
TGF-b was attributed to decreased infiltration of in-
flammatory cells, but [11] changes in MMP expression
and activity were not investigated. Recent investiga-
tion suggests that glomerular and interstitial macrophage
accumulation and activation accompany prolonged hy-
perglycemia, and both correlate with renal fibrosis and
albuminuria in the db/db mouse, a model of diabetic
nephropathy [46]. Thus, it is possible that decreased
TGF-b in diabetic PAI-1−/− mice results from decreased
inflammatory events in PAI-1−/− mice. However, it is un-
clear whether glomerular inflammation plays a major role
in the STZ model of diabetic nephropathy.
Another mechanism may involve PAI-1 stimulation of
intracellular ERK/MAPK signaling by binding to uPA
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complexed to uPAR, which is independent of its enzy-
matic action to convert plasminogen to plasmin [25, 47,
48]. Mesangial cells express uPAR and, thus, can poten-
tially respond to PAI-1. We found that PAI-1 stimula-
tion of TGF-b in mesangial cells was attenuated by (1)
blocking antibody of uPA binding to uPAR, (2) uPA,
and (3) inhibition of MAPK activity demonstrating a
role for uPAR and MAPK. In diabetic kidney cortex,
uPAR, PAI-1, and TGF-b expression is significantly up-
regulated [49, 50]. Previous studies demonstrated that
uPA/PAI-1/uPAR complexes with integrins, which are
then inactivated [1]. Our data suggest that uPAR bound to
either uPA or PAI-1 alone increases mesangial TGF-b ex-
pression; however, uPA inhibited PAI-1–induced TGF-b
expression possibly because the complex enhances degra-
dation of integrins that are also necessary for TGF-b reg-
ulation [51]. Further studies are necessary to define these
mechanisms. Nevertheless, these observations provide
evidence that PAI-1 directly regulates TGF-b expression
and hence, ECM production through uPAR binding and
subsequent activation of ERK/MAPK signaling. Thus, in
diabetic PAI-1−/− mice, decreased renal TGF-b is likely
due to the lack of PAI-1, although as discussed above,
other potential mechanisms may exist.
Plasmin can stimulate TGF-b , but the present inves-
tigation underscores a critical role of PAI-1 in diabetic
glomerulosclerosis and uncovers a new, previously un-
defined mechanism of PAI-1 in fibrosis. PAI-1 itself can
stimulate TGF-b to ultimately regulate ECM production.
Thus, in the diabetic milieu of hyperglycemia, increased
Ang II, hypertension (mesangial stretch) and other fac-
tors, two vicious cycles of reciprocal stimulation between
PAI-1 and TGF-b perpetuate the fibrotic response. These
factors stimulate both TGF-b and PAI-1 which transcrip-
tionally regulate each other, creating a potentially esca-
lating cycle to enhance accumulation of ECM. Both cycles
appear to be MAPK-dependent since this signaling path-
way regulates transcription of both PAI-1 and TGF-b .
Inhibition of PAI-1 and TGF-b expression is important
to attenuate glomerular fibrosis, either by treating each
of the factors in the diabetic milieu independently (such
as aggressive glucose control, ACE inhibitors, ARBs, or
blood pressure lowering) or perhaps collectively by in-
hibiting MAPK signaling [52]. Inhibitors of PAI-1 bind-
ing to uPAR may also be a fruitful approach in treatment
and prevention of diabetic nephropathy.
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